SLC5A2 and diabetes mellitus: The major concern about the peri‐operative use of SGLT2 inhibitors is the development of diabetic ketoacidosis (DKA) and particularly euglycaemic DKA and ketoacidosis in those with or without diabetes mellitus, where the glucose concentrations are normal (i.e. < 11.0 mmol.l‐1).